簡 麗年

Medicine & Life Sciences

1. Taiwan 100%
2. Cohort Studies 51%
3. Population 40%
4. Stroke 29%
5. Medicaid 25%
6. National Health Programs 23%
7. Myocardial Infarction 21%
8. Uterine Cervical Neoplasms 19%
9. Atrial Fibrillation 19%
10. Hospitalization 18%
11. Case-Control Studies 17%
12. Drug-Eluting Stents 16%
13. Parkinson Disease 16%
14. Percutaneous Coronary Intervention 15%
15. Epilepsy 14%
16. Propensity Score 14%
17. Breast Neoplasms 13%
18. Mortality 13%
19. Databases 12%
20. Metformin 12%
21. Dry Eye Syndromes 12%
22. Chronic Obstructive Pulmonary Disease 12%
23. Hip Replacement Arthroplasties 12%
24. Renal Dialysis 12%
25. Comorbidity 11%
26. Chronic Kidney Failure 11%
27. Survival 10%
28. Therapeutics 10%
29. Dementia 9%
30. Vertebroplasty 9%
31. Anemia 9%
32. Non-ST Elevated Myocardial Infarction 9%
33. Rivaroxaban 9%
34. Safety 9%
35. Compression Fractures 8%
36. Clopidogrel 8%
37. Diabetes Mellitus 8%
38. Hydroxymethylglutaryl-CoA Reductase Inhibitors 8%
39. Heart Failure 8%
40. Kidney 8%
41. Registries 7%
42. Anorexia Nervosa 7%
43. Proton Pump Inhibitors 7%
44. Type 2 Diabetes Mellitus 7%
45. Gastroesophageal Reflux 7%
46. Women's Health 7%
47. Warfarin 7%